glp-1 drugs pharmaceutical companies news 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 insurance coverage worsened at

The entire study is built on a foundation of sand

Milkovic L, Zarkovic N, Marusic Z, Zarkovic K, Jaganjac M

Check out the links to the original studies at the end of this article

Others are injectables, but if dosage frequency is a concern, there are once-weekly options to choose from

Newly Identified Side Effect Dysesthesia: Skin sensitivity or tingling reported in 20.9% of patients at the highest dose Other Common Side Effects Nausea: 43% Diarrhea: 33% Vomiting: 21% Retatrutide FAQs: Approval, Results, Cost & Access Is Retatrutide FDA approved as of January 2026

Notably, these children were not medicated for ADHD as in New Zealand, the practice of drugging children was not common back in the 1970s